NONOF - Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet
- Vir Biotechnology and GlaxoSmithKline expect to develop 2 million doses of Covid-19 antiviral Sotrovimab in the 1st half of 2022, with more to follow in the 2nd half of 2022.
- An Emergency Use Authorization of Sotrovimab has been filed as an intramuscular injection for patients with mild to moderate Covid-19 to give patients another delivery option.
- VIR-2218 is an RNAi drug being explored in many combinations for the treatment of patients with Hepatitis B. Most notable combination thus far is VIR-2218 together with pegylated interferon alpha.
- Additional drugs in the pipeline are VIR-1111 as a prophylaxis for HIV and VIR-2482 as a prophylaxis for Hepatitis A.
For further details see:
Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet